Pamoja Capital

Mindgram is a science-based platform and mobile application focused on enhancing mental wellness. It aims to improve productivity by addressing stress and burnout through a range of services. The platform provides daily personalized coaching, psychological support for employees, and group workshops that can be conducted via chat or video calls. Mindgram enables employees to cultivate essential skills and effectively manage workplace challenges, fostering a healthier work environment.

The Nue Co. Ltd. is a London-based company that specializes in producing nutritional supplements made from organic ingredients. Established in 2016, The Nue Co. focuses on creating products such as vitamins, milk protein, plant protein, magnesium, prebiotics, and probiotics, with an emphasis on traceability and quality. The company's formulation approach is rooted in simplicity and creativity, utilizing powerful organic foods rich in specific nutrients rather than artificial additives. Their supplements are free from toxic preservatives, flavorings, and sweeteners, ensuring that every ingredient is responsibly sourced and clinically validated. Additionally, The Nue Co. operates an online subscription platform for product distribution, while prioritizing environmentally friendly practices by limiting plastic packaging and striving to reduce their carbon footprint. Their mission is to provide science-backed supplements that promote overall health and wellness.

Mindgram is a science-based platform and mobile application focused on enhancing mental wellness. It aims to improve productivity by addressing stress and burnout through a range of services. The platform provides daily personalized coaching, psychological support for employees, and group workshops that can be conducted via chat or video calls. Mindgram enables employees to cultivate essential skills and effectively manage workplace challenges, fostering a healthier work environment.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.

Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, focused on developing non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company specializes in formulating volatile anesthetics to alleviate discomfort associated with procedures such as venipuncture, venous cannulation, and minor dermatological interventions. Vapogenix's products are designed to provide effective pain relief at the source, particularly for hospitalized children undergoing venous access procedures. By utilizing these innovative analgesics, Vapogenix aims to enhance patient comfort, reduce procedural anxiety, and improve the efficiency of healthcare providers.

Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, focused on developing non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company specializes in formulating volatile anesthetics to alleviate discomfort associated with procedures such as venipuncture, venous cannulation, and minor dermatological interventions. Vapogenix's products are designed to provide effective pain relief at the source, particularly for hospitalized children undergoing venous access procedures. By utilizing these innovative analgesics, Vapogenix aims to enhance patient comfort, reduce procedural anxiety, and improve the efficiency of healthcare providers.